MOBI Stock Forecast & Price Target

Mobia Medical is attractive because Vivistim appears to address a large, underpenetrated market with no other FDA-approved chronic stroke recovery device, supported by ~9M ischemic stroke survivors and a clear unmet need beyond the 3-to-6 month rehab window. Clinical evidence is increasingly compelling, with two-year VNS-REHAB data showing 76% of participants achieved a clinically meaningful response, average FMA-UE gains of +7.5 points, and durable quality-of-life improvements that reinforce the therapy’s differentiation. Commercially, the company is already scaling from its full launch in 2023 with over 1,000 implants, 2Q26 revenue of $13.5M up 102% year over year, and improving reimbursement dynamics that should help accelerate adoption.

Mobia Medical is facing a negative setup because its downside case depends on weaker-than-expected Vivistim adoption, with fewer new stroke centers coming on board than modeled and overall market growth potentially slowing. The company is also vulnerable to faster average selling price degradation, which would pressure revenue quality, while longer product development timelines could delay commercialization benefits and limit near-term operating leverage. In addition, higher operating expense spend than modeled would further strain profitability, making the business more exposed to execution risk because all revenue currently depends on Vivistim sales to primary and comprehensive stroke centers in the United States.